Zenotech Laboratories is a pharmaceutical factory that works for a single customer: it makes complex sterile injectables and biotechnology products exclusively for Sun Pharmaceutical Industries, its parent company, under a loan-licensing arrangement where Sun Pharma owns the drug licences and Zenotech earns a conversion fee for every unit it produces. The company was incorporated in 1989 but its modern shape was forged by a court-ordered management takeover in 2011, after litigation with its original promoters, and then cemented in 2022 when Sun Pharma bought out the minority promoter stake held by Daiichi Sankyo, taking its ownership to nearly 69%. The recurring logic is simple: Zenotech is a dedicated manufacturing arm that runs Sun Pharma’s formulations through its own plant and equipment, charging for the service rather than selling products itself - a model that has made the company debt-free and operationally profitable since FY20.
Business segments
A single engine - contract manufacturing of sterile injectables and oral solids for one parent, with a side stream from leasing out its biotech facility to the same customer.
1. Contract manufacturing for Sun Pharma: the factory that runs on a parent’s licences
Every rupee Zenotech earns comes from Sun Pharma - either as a job-work fee for manufacturing drugs or as rent for its biotech equipment and facility.
- Paid per batch, not per bottle - the company manufactures products across four categories (long-acting depot injectables, eye-care formulations, oncology oral and injectable drugs, and general injectables) and is paid agreed conversion charges for the job work, meaning its revenue depends on production volumes rather than the market price of the medicines.
- One campus, six production lines - its Hyderabad site houses an oral solid dosage facility for tablets and capsules, an eye-care unit, a cytotoxic injectables line for cancer drugs, a general injectables line, a depot injectables facility commissioned in late FY20, and a biotech unit that was renovated and handed over to Sun Pharma for R&D in mid-2021.
- Utilisation follows the parent’s order book - by FY20 the oral solids and eye-care lines were running at full installed capacity, while the cytotoxic and general injectables lines were underutilised because of low market demand from Sun Pharma; the depot injectables line had only just begun production. By FY22, volumes across all dosage forms had improved after two sluggish years.
- No raw-material risk, no sales risk - the company does not buy active pharmaceutical ingredients or sell finished drugs to the market; its main input costs are power, fuel, plant repairs, consumables, quality-control testing, and contract manpower, and it has no direct commodity exposure or foreign-exchange risk.
Group structure and partners
Zenotech is a listed subsidiary of Sun Pharmaceutical Industries, which holds 68.84% and is the sole promoter - the company has no other operating entities, joint ventures, or associates.
- Sun Pharma became the sole promoter in 2022 - it acquired Daiichi Sankyo’s entire 11.28% stake in an off-market transaction at ₹7.73 per share, lifting its holding from 57.56% to 68.84%; Daiichi Sankyo was reclassified as a public shareholder in early 2023.
- Three overseas subsidiaries exist only on paper - Zenotech’s entities in Brazil, the USA, and Nigeria are all defunct, cancelled, or wound up, and the company cannot prepare consolidated accounts because the statutory books from the pre-2011 management era are missing.
- No debt, no joint ventures, no associates - the company repaid its term loan from Sun Pharma during FY23 and carries zero non-current borrowings; it has no material subsidiaries under SEBI rules and no other corporate relationships beyond the parent.